drugset / Trial / NCT07340138
Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
NaSingle-groupOpen-labelTreatment
Summary
This Phase 1b, multicenter, open-label study aims to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of pelabresib as add-on to ruxolitinib in Japanese patients with myelofibrosis (MF).
Timeline
- Start
- 2026-04-15
- Primary completion
- 2026-07-23
- Completion
- 2030-09-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pelabresib | Small molecule | 125 mg | Oral |
| Background | Ruxolitinib | Small molecule | 5 mg | — |
| Background | Ruxolitinib | Small molecule | 25 mg | — |